Global Herbal Medicine Market Projected to Reach US$600 Billion by 2030, OMAI Phytopharmaceuticals Aiming for Global Expansion

The global herbal medicine market is on a growth trajectory towards US$600 billion by 2030. While Traditional Chinese Medicine (TCM) from China and Ayurveda from India are currently the dominant global forces, Indonesia is preparing to establish itself on the world stage. The nation possesses the second-largest biodiversity in the world, after Brazil, with over 30,000 species of medicinal plants, supported by international-standard scientific research.

Indonesia aims to act not merely as a supplier of raw materials, but as a producer of modern natural medicines that meet global standards. Professor Raymond R. Tjandrawinata, Director of Business Development and Scientific Affairs at PT Dexa Medica, emphasised that the success of China and India lies in their courage to build healthcare ecosystems that fully integrate herbal medicine into modern medical services.

‘Indonesia has the second-largest biodiversity in the world. The next step is to build a healthcare system that integrates biodiversity-based medicines into formal healthcare services, just as China and India have proven,’ stated the Professor Emeritus of Pharmaceutical Biotechnology at Atma Jaya Catholic University of Indonesia in Jakarta.

It is noted that China has integrated TCM as an essential part of its national hospital system, leading to its acceptance as a global herbal drug. Similarly, India has established national-scale Ayurveda hospitals supported by robust research and clinical trial ecosystems. Both nations demonstrate that natural wealth, when supported by science and integrated systems, can create a world-class healthcare industry. Indonesia possesses these foundational elements, and Dexa Group intends to turn this potential into reality.

For over two decades, Dexa Group, through Dexa Laboratories of Biomolecular Sciences (DLBS), has consistently developed Integrative Modern Natural Medicine (OMAI) based on modern science and evidence-based medicine. This process involves in-depth research, the standardisation of natural ingredients, and rigorous clinical trials to ensure the efficacy and safety of every product produced.

‘We have already exported Indonesian phytopharmaceuticals to several countries, such as the Philippines and Cambodia. Medical professionals there use and recommend Indonesian products because their international standards, efficacy, and safety have been proven,’ explained Raymond.